Younossi ZM, Stepanova M, Anstee QM, et al. - Since patient-reported outcomes (PROs) are used to measure the experience of patients with their disease, however, there are few PRO data from NASH patients, researchers gathered data from the STELLAR clinical trials to evaluate PROs for NASH and advanced fibrosis. Data were analyzed from 1,667 patients with NASH and bridging fibrosis or compensated cirrhosis enrolled in the phase 3 STELLAR trials of selonsertib who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment beginning. Cirrhosis, female gender, higher BMI, smoking history, and diabetes or other comorbidities were factors independently related to lower PRO scores in multivariate regression analysis. The authors discovered that PROs are significantly lower in NASH patients with advanced fibrosis who partook in the STELLAR clinical trials. Treatment of NASH patients should focus not only on improving clinical outcomes but also on quantifiable symptom burden and quality of life-related to health.